Stocks Health care PLRX
NASDAQ · Health carePliant Therapeutics, Inc. (PLRX)
It posted a net loss of $92.3M. In fiscal 2025 capital spending exceeded operating cash flow by $128.7M. At June 30, 2026 it held $24.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Pliant Therapeutics, Inc.
- Net worth
- Pliant Therapeutics, Inc. has a market value (market cap) of $49.5M at the latest share price, and shareholders' equity of $146.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0, with a net loss of $149.3M.
- Cash flow
- In fiscal 2025 operations used $128.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Pliant Therapeutics, Inc.'s next report is expected around November 23, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Pliant Therapeutics, Inc. does
Pliant Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PLRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$149.3M | -$2.43 | -$128.7M |
| 2024 | $0 | -$210.3M | -$3.47 | -$159.4M |
| 2023 | $1.6M | -$161.3M | -$2.75 | -$117.3M |
| 2022 | $9.7M | -$123.3M | -$2.94 | -$96.4M |
| 2021 | $7.6M | -$97.3M | -$2.71 | -$77.4M |
| 2020 | $41.8M | -$41.5M | -$1.95 | -$38.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Pliant Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026
- July 13, 2026
- June 11, 2026
- May 11, 2026
- May 11, 2026
- April 22, 2026
- April 22, 2026Additional proxy material DEFA14A
Insider trades
What the people running Pliant Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| January 20, 2026 | Kuo MinnieChief Operating Officer | Soldpre-planned (10b5-1) | 6,917 | $8.9K |
| January 20, 2026 | Coulie BernardPresident and CEO, Director | Soldpre-planned (10b5-1) | 89,375 | $114.4K |
| January 20, 2026 | Cheung LilyChief Human Resource Officer | Soldpre-planned (10b5-1) | 7,534 | $9.6K |
| January 20, 2026 | Cummings Keith LamontChief Financial Officer | Soldpre-planned (10b5-1) | 24,002 | $30.7K |
Who owns PLRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Tang Capital Management, LLC13D, may seek influence with 6 related filers | 9.6% | March 10, 2025 |
| ADAR1 Capital Management, LLC13G, passive with 1 related filers | 8.9% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 86 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Tang Capital Management LLC | 6,141,261 | -1,871 |
| ADAR1 Capital Management, LLC | 5,509,724 | +2,924,598 |
| Vanguard Capital Management LLC | 2,440,351 | +97,250 |
| Two Sigma Investments, LP | 2,262,832 | +9,694 |
| Citadel Advisors LLC | 2,142,226 | -1,084,373 |
| Renaissance Technologies LLC | 2,049,874 | +197,032 |
| Monaco Asset Management SAM | 1,938,747 | 0 |
| Lynx1 Capital Management LP | 1,798,070 | new |
| BML Capital Management, LLC | 1,546,137 | 0 |
| Prosight Management, LP | 1,370,233 | -297,367 |
| Peapod Lane Capital LLC | 1,309,013 | +20,435 |
| Woodline Partners LP | 1,296,534 | -370,296 |
| BlackRock, Inc. | 1,151,214 | +54,784 |
| Ikarian Capital, LLC | 1,000,000 | new |
| Eversept Partners, LP | 891,425 | 0 |
| Marshall Wace, Llp | 835,124 | -160,849 |
| Redmile Group, LLC | 772,126 | 0 |
| Jpmorgan Chase & Co | 681,647 | -180,176 |
| Jacobs Levy Equity Management, Inc | 643,120 | -75,423 |
| Geode Capital Management, LLC | 578,577 | +161,303 |
Insiders
4 insiders reported holding 885,468 shares in total, about $708K at the last price.
| Holder | Shares |
|---|---|
| Coulie BernardPresident and CEO, Director | 505,601 |
| Cummings Keith LamontChief Financial Officer | 297,214 |
| Cheung LilyChief Human Resource Officer | 44,847 |
| Kuo MinnieChief Operating Officer | 37,806 |
Questions about PLRX
What does Pliant Therapeutics, Inc. do?
Pliant Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as PLRX. Its shares trade on NASDAQ under the ticker PLRX.
What is Pliant Therapeutics, Inc.'s net worth?
Pliant Therapeutics, Inc. has a market value (market cap) of $49.5M at the latest share price, and shareholders' equity of $146.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Pliant Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $92.3M.
When did Pliant Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 2, 2026.
When is Pliant Therapeutics, Inc.'s next earnings report?
Pliant Therapeutics, Inc.'s next report is expected around November 23, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PLRX with
Follow PLRX
Get an email when Pliant Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Pliant Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.